Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FTXH vs MDEV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FTXH Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 3–0 Matrix Metrics)

FTXH Overall Winner 6-Pillar Tally: FTXH 0 – 0 MDEV (6 Tie) Matrix Metrics: FTXH 3 – 0 MDEV

As of Nov 16, 2026, First Trust Nasdaq Pharmaceuticals ETF (FTXH) is the stronger overall head-to-head candidate over First Trust Indxx Medical Devices ETF (MDEV) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). FTXH carries a Unified Composite Score of 50.1/100 (HOLD) at $43.87 (N/M Forward P/E, N/A operating margin), whereas MDEV carries 41.2/100 (SELL) at $22.56 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FTXH vs MDEV
FTXH NASDAQ Head-to-Head Winner
First Trust Nasdaq Pharmaceuticals ETF
Institutional Equity
$43.87
-0.81% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 22% Vol
Unified Composite Score
50.1 / 100 HOLD
Tech 43.0 Fund 45.0 Flow 50.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.2% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $43.66 · SMA50: $42.13
MDEV Cboe BZX
First Trust Indxx Medical Devices ETF
Institutional Equity
$22.56
-0.33% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.55β · 25% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 31.0 Fund 43.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 57
RSI-14: 57.5 · SMA20: $22.34 · SMA50: $21.35

6-Pillar Scorecard Institutional Category Breakdown (FTXH 0 – 0 MDEV)

Columns: Metric · FTXH · MDEV
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 213.6% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FTXH (3) vs MDEV (0)
Institutional Metric FTXH MDEV Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
91% ($31–$45) 86% ($18–$23) Stronger Trend FTXH
Beta / 30D Volatility
Risk Regime
0.46β · 22% Vol 0.55β · 25% Vol Lower Realized Risk FTXH
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 41.2 / 100 (SELL) Higher Composite FTXH
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MDEV +0.46 pp
FTXH: +5.3% · MDEV: +5.76%
3M Horizon FTXH +1.74 pp
FTXH: +7.91% · MDEV: +6.17%
6M Horizon FTXH +6.85 pp
FTXH: +30.18% · MDEV: +23.33%
1Y Horizon FTXH +30.9 pp
FTXH: +39.25% · MDEV: +8.35%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FTXH vs MDEV. Trailing 12-month operating profitability (FTXH N/A vs MDEV N/A) and valuation multiples (FTXH N/M vs MDEV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FTXH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
MDEV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FTXH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 213.6%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FTXH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MDEV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MDEV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FTXH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MDEV Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FTXH vs MDEV Key Questions & Quantitative Answers

As of Nov 16, 2026, First Trust Nasdaq Pharmaceuticals ETF (FTXH) is the stronger overall head-to-head candidate over First Trust Indxx Medical Devices ETF (MDEV) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). FTXH carries a Unified Composite Score of 50.1/100 (HOLD) at $43.87 (N/M Forward P/E, N/A operating margin), whereas MDEV carries 41.2/100 (SELL) at $22.56 (N/M Forward P/E, N/A operating margin). Technically, FTXH sits in a Markup phase (RSI 55.3, UNCLASSIFIED options structure) and MDEV sits in a Markup phase (RSI 57.5, UNCLASSIFIED options structure).

FTXH and MDEV split Growth & Scale metrics: FTXH posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MDEV at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, FTXH generates N/A in USD-normalized revenue versus N/A for MDEV. In operating R&D and SG&A reinvestment, FTXH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MDEV.

FTXH and MDEV trade at balanced relative valuation multiples. FTXH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MDEV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FTXH (N/A ROE) versus MDEV (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, FTXH carries 213.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 22% Vol realized risk). By comparison, MDEV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 25% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.